Goldman Sachs Maintains Buy on Taysha Gene Therapies, Raises Price Target to $13
Taysha Gene Therapies Inc TSHA
$5.86
▼ -0.26%
($-0.02)
🗓️ Earnings Next Week
Open
$5.88
Prev Close
$5.88
Day Range
$5.73 – $5.92
52W Range
$2.54 – $7.30
Market Cap
$1.87B
Beta
1.27
EPS (TTM)
$-0.38
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-09-24 |
| Shares Out. | 319,780,000 |
| Website | tayshagtx.com/ ↗ |
| Phone | 12146120000 |
| Employees | 99 |
| Net Income | -$42.4M |
| Free Cash Flow | -$112.7M |
| Total Assets | $300.4M |
| Total Liabilities | $88.4M |
| Equity | $211.9M |
About Taysha Gene Therapies Inc
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
Taysha Gene Therapies Inc is a publicly traded company under the ticker symbol TSHA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
19 analysts (2026-07-01)